Daiichi Sankyo is set to present new findings from its breast cancer research portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS25), showcasing more than 30 abstracts focused on the DXd antibody drug conjugate portfolio. The presentations will include four rapid-fire mini-oral sessions along with additional updates from five landmark trials evaluating ENHERTU (trastuzumab deruxtecan) and DATROWAY (datopotamab deruxtecan) across multiple breast cancer subtypes.
Health Technology Insights: Alphaeon Announces Partnership with Women in DSO
The rapid-fire sessions will highlight ENHERTU data in both curative-intent and metastatic settings for patients with HER2 positive breast cancer. Two of these presentations will focus on findings from the DESTINY-Breast11 phase 3 trial, including patient-reported outcomes and safety analyses of ENHERTU administered after paclitaxel, trastuzumab, and pertuzumab compared to dose-dense doxorubicin and cyclophosphamide followed by THP in the neoadjuvant setting for patients with high-risk, locally advanced early-stage HER2 positive breast cancer. Additional efficacy and safety results from the DESTINY-Breast05 phase 3 trial comparing ENHERTU to trastuzumab emtansine as a post-neoadjuvant therapy in patients with residual invasive disease will also be featured. The fourth session will cover patient-reported outcomes from the ENHERTU plus pertuzumab arm of the DESTINY-Breast09 trial evaluating first-line treatment for HER2 positive metastatic breast cancer. Interim results from this trial were recently published in The New England Journal of Medicine, marking the eighth pivotal trial of ENHERTU featured in the journal.
Health Technology Insights: LCMC Health Selects Nabla to Power Systemwide Ambient AI Implementation
Other notable updates include final analysis and five-year follow-up results from the DESTINY-Breast03 trial, which compared ENHERTU to T-DM1 in second-line treatment for HER2 positive metastatic breast cancer, and further safety data from the TROPION-Breast02 phase 3 trial of DATROWAY. DATROWAY represents the first therapy to demonstrate a significant overall survival improvement versus chemotherapy as a first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer who are not candidates for immunotherapy.
“Our recent findings across these five landmark trials illustrate the potential of the DXd antibody drug conjugate portfolio to reshape standards of care for breast cancer patients,” said Ken Takeshita, MD, Global Head of R&D at Daiichi Sankyo. “We remain committed to advancing research and collaborating with the breast cancer community to deliver innovative treatments that make a meaningful difference for patients.”
Additional data to be highlighted at SABCS will include an exploratory post-hoc analysis by hormone receptor status from the DESTINY-Breast12 trial evaluating ENHERTU in HER2 positive metastatic breast cancer patients with brain metastases. Further presentations will cover final results from the DESTINY-Breast07 trial assessing ENHERTU monotherapy and ENHERTU plus pertuzumab in previously untreated HER2 positive metastatic patients, as well as initial findings from the DESTINY Breast Respond HER2 Low Europe non-interventional study focusing on HER2 low metastatic breast cancer.
Collaborative research will also be featured, with results from four externally sponsored trials across the DXd ADC pipeline. Key presentations include interim results from the HALLOW study evaluating ENHERTU in HER2 low metastatic breast cancer in Japan and a post-hoc pooled efficacy analysis from the TUXEDO-3 trial of patritumab deruxtecan in HER2 positive metastatic breast cancer patients with brain metastases or leptomeningeal disease. Other presentations will highlight intracranial and extracranial activity of ENHERTU and DATROWAY, including a ctDNA analysis from the DEBBRAH trial and findings from the DATO-BASE trial in HER2 negative breast cancer patients with leptomeningeal disease.
Several trials-in-progress will also be presented, addressing a broad spectrum of unmet needs in breast cancer care. These include the PONTIAC trial comparing ENHERTU to CDK4/6 inhibitor-based endocrine therapy, a trial evaluating ENHERTU in combination with the EZH1/2 inhibitor valemetostat, and the TROPION-Breast06 study of DATROWAY in HR positive, HER2 IHC 0 inoperable or metastatic breast cancer. Additionally, three ongoing trials under the HERTHENA program will be highlighted, including studies evaluating patritumab deruxtecan in combination with immunotherapy or HER2-targeted agents across early-stage and metastatic breast cancer populations.
Daiichi Sankyo will also host its annual Science and Technology Day for investors on December 15, 2025, from 5:30 to 7:30 pm ET, and December 16, 2025, from 7:30 to 9:30 am JST, providing updates on research and development, business progress, and manufacturing developments across the company’s portfolio.
Health Technology Insights: Shoulder Innovations Partners with INS for Robotic Shoulder Surgery
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
